Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Ogechukwu Egini et al.|Blood|2024Cited by 7
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L. Crombie, Iris Isufi, Sairah Ahmed et al.|Blood|2026Cited by 1